Linperlisib

Peripheral T Cell Lymphoma

Ruijin HospitalSmall moleculePhase 2/3Active

B

61/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 55/ 100
Competitive Position: 73/ 100

Competitive context

135 Active assets in the Peripheral T Cell Lymphoma cohort.

Asset / Sponsor	Phase	Rating
Inno-206 BeBetter Med Inc	Phase 4	BBB
PREDNISONE TABLETS Tarapeutics Science Inc.	Phase 4	BBB
Pralatrexate Peking University People's Hospital	Phase 4	BBB
(+)-VINCRISTINE BeBetter Med Inc	Phase 4	BBB
Cyclophosphamide Tarapeutics Science Inc.	Phase 4	BBB

View all 50 →

Same molecule, other indications

Linperlisib is also rated in:

Indolent B-cell LymphomaDormant

BB

Indicative ·

65 / 100

Extranodal Natural Killer/T Cell LymphomaDormant

CCC

Indicative ·

54 / 100

relapsed/refractory diffuse large B-cell lymphomaDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.